Interstitial lung disease in autoimmune diseases

Vivek Nagaraja, Isabel Mira-Avendano, Alejandro Diaz-Arumir, Michael Gotway, Ana C. Zamora

Research output: Contribution to journalArticlepeer-review


Approximately forty percent of patients with autoimmune diseases suffer from interstitial lung disease (ILD). There are currently no specific screening guidelines for these patients. ILD causes substantial morbidity and mortality; early recognition and diagnosis are essential to avoid treatment delays. The gold standard for management incorporates a multidisciplinary approach (MMD) with input from various specialties, such as pulmonary, rheumatology, radiology, and pathology, to reach a consensus regarding diagnosis and treatment. In this article, we will discuss the most common forms of ILD that affect patients with autoimmune diseases, as well as how to promptly and effectively diagnose and treat these conditions.

Original languageEnglish (US)
Pages (from-to)S139-S153
JournalRevista Colombiana de Reumatologia
StatePublished - Apr 2024


  • Autoimmune disease
  • Collagen vascular disease
  • Interstitial lung disease

ASJC Scopus subject areas

  • Internal Medicine
  • Rheumatology
  • Immunology and Allergy
  • Health Professions (miscellaneous)
  • Rehabilitation
  • General Biochemistry, Genetics and Molecular Biology
  • Pharmaceutical Science


Dive into the research topics of 'Interstitial lung disease in autoimmune diseases'. Together they form a unique fingerprint.

Cite this